{"entity":{"id":"nct06566586","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","aka":[],"tldr":"A phase 2 trial of TQB3702 tablets+Chemotherapy regimen in non-Hodgkin lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","summary":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma is a phase 2 interventional study registered as NCT06566586 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 80 participants planned, started 2024-11-06 and due to reach its primary completion in 2026-03. Interventions recorded: TQB3702 tablets+Chemotherapy regimen.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06566586","url":"https://clinicaltrials.gov/study/NCT06566586"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06566586","phase":"2","setting":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct06566586/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"drug":[{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/"}]}}